Newsletters


Filter by volume

Agenus on Twitter

Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report Conference Call on Monday, August 9, 2021, at 8:30 a.m. ET investor.agenusbio.com/news-releases/…

@SiweiYang @ODayMD A recording of the presentation is available and can be accessed at wsw.com/webcast/blair5…

PD-1 resistance is a big challenge for I-O therapy, which the predictive potential of Agenus' VISION platform could help overcome. Listen to @ODayMD discuss this & other aspects of PD-1 resistance at the William Blair Biotech Focus Conference: investor.agenusbio.com/events/event-d…

test Twitter Media - PD-1 resistance is a big challenge for I-O therapy, which the predictive potential of Agenus' VISION platform could help overcome. 

Listen to @ODayMD discuss this & other aspects of PD-1 resistance at the William Blair Biotech Focus Conference: https://t.co/jHxx5X60DV https://t.co/7bW25dMZqG

@ZeroToStockHero @ODayMD This presentation does not begin until 4:20pm ET today. Click here to watch: wsw.com/webcast/blair5…

TUNE IN today to hear Dr. Steven O'Day @ODayMD speak on the William Blair Biotech Focus Conference 2021 panel “Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors” at 4:20pm ET. Click to listen: wsw.com/webcast/blair5…

Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021 Agenus' CMO Steven O'Day, MD @ODayMD will participate in a panel on July 14 from 4:20 - 5:20 p.m. ET Click for more information & to register: investor.agenusbio.com/news-releases/…

Is Fc enhancement required for optimal performance of anti-TIGIT molecules? Dr. @dhanschand spoke at the @sitcancer seminar "The TIGIT Pathway: A Deep Dive in Cancer Immunotherapy Targets" to address this question & discuss this emerging IO target #TIGIT sitcancer.org/events/event-d…

test Twitter Media - Is Fc enhancement required for optimal performance of anti-TIGIT molecules? 

Dr. @dhanschand spoke at the @sitcancer seminar "The TIGIT Pathway: A Deep Dive in Cancer Immunotherapy Targets" to address this question & discuss this emerging IO target #TIGIT https://t.co/7owWLMRZhQ https://t.co/QRAnWW7Qp1

Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777 Phase 1 dosing for AGEN1777 is expected to begin during the third quarter of 2021. @bmsnews investor.agenusbio.com/news-releases/…

Agenus' latest newsletter now available: A Strategy for Innovation: Significant Strides in the Field of I-O Since its founding Agenus has used its deep knowledge of the immune system's biology to create therapies to optimally target cancer. Read more: agenusbio.com/newsletters/ag…

June is Cancer Immunotherapy Month! At the World Vaccine Congress last month, Agenus' CMO @ODayMD spoke about how #immunotherapy has changed the landscape of cancer treatment and continues to evolve to provide benefit to even more #cancerpatients. #CIM21 investor.agenusbio.com/events/event-d…

Hear Agenus' Head of Drug Discovery Dr. Dhan Chand speak at the SITC seminar "The TIGIT Pathway: A Deep Dive in Cancer Immunotherapy Targets" TODAY from 2-4pm ET! Click here to register and watch: sitcancer.org/events/event-d… @dhanschand @sitcancer #immunotherapy #TIGIT

test Twitter Media - Hear Agenus' Head of Drug Discovery Dr. Dhan Chand speak at the SITC seminar "The TIGIT Pathway: A Deep Dive in Cancer Immunotherapy Targets" TODAY from 2-4pm ET! Click here to register and watch: https://t.co/lkjgbDTLV6 
@dhanschand @sitcancer #immunotherapy #TIGIT https://t.co/5heoLuRMHc

Agenus' Head of Drug Discovery Dhan Chand, PhD @dhanschand will speak at a @sitcancer seminar on #TIGIT on June 29 at 2 - 4pm EST. Mark your calendars to join the discussion on this exciting #Immunotherapy target! Register here: sitcancer.org/education/deep… twitter.com/sitcancer/stat…

Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer The FDA has set a target action date of December 16, 2021. investor.agenusbio.com/news-releases/…

$AGEN listed as one of biggest #ASCO21 risers in @evaluatevantage stock round-up. Agenus presented on differentiated activity of anti-PD-1 antibody balstilimab & new clinical data on AGEN2373, a CD137 agonist antibody evaluate.com/vantage/articl…

Agenus at #ASCO21 Agenus’ CMO @ODayMD offers his thoughts on Agenus' #AI VISION platform and AGEN2373 data presented @ASCO. Click to read more: investor.agenusbio.com/news-releases/…

test Twitter Media - Agenus at #ASCO21
Agenus’ CMO @ODayMD offers his thoughts on Agenus' #AI VISION platform and AGEN2373 data presented @ASCO. Click to read more: https://t.co/6DQC2Q75te https://t.co/CSqifhWc0R

Agenus’ Presentations at #ASCO21 Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373 Bal demonstrates superior tumor killing potential in a VISION study. AGEN2373 shows no liver toxicity; combo trials are planned investor.agenusbio.com/news-releases/…

Agenus' collaboration with @bmsnews will allow us to accelerate the advancement of our differentiated pipeline while also giving us greater optionality as we pursue the best development strategy for each individual asset. investor.agenusbio.com/news-releases/…

test Twitter Media - Agenus' collaboration with @bmsnews will allow us to accelerate the advancement of our differentiated pipeline while also giving us greater optionality as we pursue the best development strategy for each individual asset.

https://t.co/hrT0IaZQ95 https://t.co/aTXoTlwhUj

Agenus newsletter now available: Setting the Stage for Innovation with Our Own PD-1 Having a PD-1 is critical to our I-O strategy. It provides commercial flexibility & opportunities to advance this agent for strategic combinations Click to read: agenusbio.com/agenusnews-vol…

Agenus to Participate in Fireside Chat at the @Jefferies 2021 Virtual Healthcare Conference Agenus' President and COO @jbuell01 will participate in a fireside chat on Friday, June 4, 2021 from 10:30am - 10:55am ET investor.agenusbio.com/news-releases/…